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We report the encapsulation of the hydrophilic model 
molecule calcein in the Zr-based MOF UiO-66, followed by 
amorphization of the framework by ball-milling. We show 
controlled release of calcein over more than 30 days, 
compared with the 2 day release period from crystalline UiO-
66. 
Drugs in the form of chemical and bioactive compounds are 
widely used as therapeutic agents to improve health and to 
extend the lifespan of the human population. Many of these 
compounds are successful candidates for the treatment of 
severe illnesses such as cancer. However, they can also have 
significant disadvantages, including poor solubility and non-
selective biodistribution, which often results in the damage of 
healthy tissues1 and cardiotoxicity effects,2,3 which strongly 
limits their therapeutic potential. By making use of a drug 
delivery system (DDS), most of these issues can be overcome 
through the increment of drug solubility, protection from 
degradation, controlled drug release, provision of targeted 
delivery, and a decrease in toxic side effects. Finding an 
effective DDS for therapeutic agents has been an ongoing 
challenge in bioengineering. In this context, metal-organic 
frameworks (MOFs) have emerged as potential candidates 
owing to their distinctive characteristics, such as high pore 
volumes, large surface areas, multiple topologies and tuneable 
pore size and surface chemistry.4,5 MOFs are synthesized in a 
self-assembly process from metal ions or clusters, acting as 
coordination centres that are interconnected by organic ligands. 
In recent years, MOFs have proven to be able to encapsulate 
and delivery drugs efficiently by adsorbing them in their pore 
structures. Amongst others, Horcajada et al. have loaded 
different anticancer and antiviral agents into MOFs;6 Morris et 
al. encapsulated and delivered the vasodilator agent nitric oxide 
gas (NO);7 Lin et al. reported the use of MOFs for the co-
delivery of the anticancer cisplatin molecule, and siRNA to 
enhance therapeutic effect.8 Some of the principal advantages 
of MOFs compared with other organic (e.g. liposomes and 
micelles) and inorganic (e.g. zeolites and mesoporous silicas) 
DDSs are their high loading capacities and the possibility of 
chemically functionalizing the materials to enhance drug 
affinity and to target cells. Very recently, we performed a 
computational screening study showing how MOFs can 
encapsulate up to 2 g of a drug per gram of porous solid, a 
much higher capacity than what can be found in mesoporous 
silicas and organic carriers – typically up to 0.3 mg/g.9,10  
The relatively poor chemical stability of the MOF family 
tempers many of their advantages for industrial applications. 
Such chemical instability can be considered advantageous in 
drug delivery processes, since, unlike e.g. mesoporous silicas, 
MOF DDS can be easily biodegraded in the body after the drug 
has been released. Limitations in their use do still remain 
however, such as very fast kinetic deliveries of under 3 days 
from a variety of MOF-drug systems.6,11 
An increasing awareness of amorphous MOFs12 (amMOFs, 
i.e. highly disordered framework structures retaining the basic 
metal-ligand connectivity of crystalline MOFs, though lacking 
any long range order)  in recent years has led to the use of ball-
milling to trap guest molecules by irreversibly collapsing 
porous networks around occluded species such as molecular 
I2.
13,14 Building on this concept, we hypothesized that loading of 
a therapeutic agent, followed by subsequent structural collapse 
by ball-milling, could be used to achieve prolonged controlled 
release in solution. In this scenario, the delivery process will be 
at least partially controlled by material degradation (i.e. 
dissolution) in addition to drug diffusion through the porous 
network. 
In order to probe this hypothesis, we selected in this study 
calcein as a model drug due to its structural similarities to 
doxorubicinin, a well-known anti-cancer drug. We also choose 
calcein due to its hydrophilic character, which means it cannot 
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cross cell membranes, and therefore requires a DDS to enter 
into cells. In addition, being a fluorescent molecule, it can be 
easily traced by confocal microscopy and, due to its self-
quenching characteristics, high local concentrations of calcein 
(e.g. when it is adsorbed in a MOF before being delivered) 
cannot be detected until it is released from the material.15 We 
used the UiO-66 MOF, [Zr6O4(OH)4(BDC)6] (BDC = 1,4-
benzenedicarboxylate) as a DD vehicle. UiO-66 has a cubic 
structure based on Zr oxo-clusters and BDC ligands,16 and 
possesses high thermal and chemical stability combined with a 
large porosity (SBET = 1200 m
2g-1, Vp = 0.5 cm
3g-1) formed by 
two main cavities (ca. 11 and 8 Å Øcavity).
17 Additionally, Zr has 
low toxicity (zirconyl acetate lethal dose LD50 ~4.1 mg/ml in 
rats; furthermore, the human body contains ~300 mg of Zr and 
the amount daily ingested is ~3.5 mg/day).18  
We first loaded calcein into UiO-66 by suspending the 
activated MOF into a calcein low concentration solution 
producing the cal@UiO-66 sample, which retained the structure 
of the original UiO-66 after drug loading (Fig. 1). Subsequent 
ball-milling on the empty UiO-66 framework produced an X-
ray amorphous product which we term cal@amUiO-66. Figure 
S1 (electronic supporting information, ESI) shows the scanning 
electron microscopy (SEM) pictures of UiO-66 and 
cal@amUiO-66, with particle sizes of 261 ± 12 and 272 ± 157 
nm, respectively. The morphology of the particles after 
amorphization is clearly less homogeneous, which we ascribe 
to particle compaction during the intense mechanical ball-
milling process. Figure S2 shows the thermogravimetric 
analysis (TGA) of UiO-66, with a first weight lost below 
100ºC, which corresponds to the desorption of solvent 
molecules, followed by the solid degradation at ca. 475ºC. 
Additionally, cal@UiO-66 shows another step at ca. 400ºC, 
which corresponds to the calcein desorption from the material. 
The amount of calcein loaded, measured by TGA, was 4.9 ± 0.2 
wt.%. In comparison, degradation of free calcein occurs at 
165ºC approximately. These results show the successful 
adsorption of calcein in UiO-66. We decided not to increase the 
calcein loading in order to avoid self-quenching and aid 
confocal microscopy imaging (vide infra). 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1. Powder X-ray diffraction (PXRD) patterns of synthesized UiO-66, 
cal@UiO-66 and cal@amUiO-66 compared with the calculated one for UiO-66. 
Figure 2 and S3 show the drug delivery profiles obtained for 
cal@UiO-66 and cal@amUiO-66. UiO-66 releases all the 
calcein within 2 days; similar values have been found already 
for caffeine on UiO-66.17 Interestingly, amUiO-66 shows a 
significantly slower, sustained release, prolonging the delivery 
time up to 30 days, i.e. an order of magnitude higher than its 
crystalline counterpart. Indeed, the calcein releases by the 
crystalline and amorphous frameworks during the first hour are 
ca. 36 and 3.5 %, respectively. After 5 hours, these amounts are 
increased to 68 and 16 % for UiO-66 and amUiO-66, 
respectively, and after 10 days, amUiO-66 still retains 33 % of 
calcein. Figure S4 shows the comparison between UiO-66 and 
amUiO-66 samples after 10 days release, where the presence of 
calcein in amUiO-66 is still evident.  
The delivery time for cal@UiO-66 is aligned with the release 
times presented in literature for other drug-MOF systems.6 In 
contrast, we were able to extend the release time in the amUiO-
66 sample by using the ball-milling process. In addition to the 
TGA results, the extended release time suggests that calcein 
was effectively adsorbed inside the material and not only in the 
external surface. Fitting of release patterns revealed a simple 
hyperbolic curve for UiO-66, whereas amUiO-66 showed a two 
term expression (full details can be found in the SI). During the 
first stage in amUiO-66, release of calcein takes place 
presumably through desorption and diffusion along the 
amorphous pore texture of the material. The second release 
stage is a much slower process that might be associated with 
the partial dissolution of defects in the amUiO-66 porous texture 
to liberate the remnants of the encapsulated calcein. Further 
work to analyse the release of calcein and dissolution of 
amUiO-66 is in progress. These results confirm that it is 
possible to use the amorphization process to trap a drug inside 
the material and to achieve a controlled, slower release. 
To the best of our knowledge, such extremely long release 
times have not been reported before for any MOF or DDS with 
similar characteristics. For example, by using a core-shell 
microsphere with a diameter of ca. 400 m, it has been possible 
to extend the release time of a water soluble drug up to 5 
days.19 The use of core-shell biodegradable microfibers has 
permitted to extended the delivery of the anticancer Paclitaxel 
(PTX) for approximately 5 days.20 Also, hydrogel systems 
 
Figure 2. (left) Calcein release during the first 5 hours and (right) 30 days from 
UiO-66, black closed circles, and amUiO-66, red open circles. Black solid and red 
dotted lines represent the kinetics of delivery, fitted using non-linear regression 
on UiO-66 and amUiO-66, respectively. 
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have been used for controlled delivery showing an important 
correlation between the network structure and the release rate. 
Indeed, hydrogel microspheres of 3-5 m of diameter showed 
release time prolonged for 13 days. However, when using 
larger hydrogel cylinders, drug release was increased up to 200 
days.21 All these systems are useful options only in the case of 
cell membrane permeable drugs and non-parenteral routes of 
administration. This is because, in contrast with our proposed 
amMOF system, the size of the carriers is not small enough (i.e. 
~200 nm) to enter into the cells or to circulate through the 
smallest capillaries.  
To evaluate the biocompatibility, drug transport and the way 
the crystalline and amorphous UiO-66 interact with cells 
crossing their membranes, we moved to in vitro studies in HeLa 
cells, which is a widely studied culture. Figure S5 shows the 
cytotoxicity activity of UiO-66, with IC50 values of 1.503 ± 
0.154 mg/ml and 1.357 ± 0.088 mg/ml for 24 and 48 h, 
respectively. Similar values are obtained for amUiO-66. 
Zirconyl acetate lethal dose LD50 is reported to be 4.1 mg/ml in 
rats.18 We consider this values promising for using UiO-66 in 
healthcare applications.  
Figure 3a and 3b show the confocal microscopy images of 
HeLa cells incubated for 24 and 48 h, respectively, for: i) the 
fixed cell control; non-fixed cells incubated with ii) free 
calcein; iii) cal@UiO-66, and iv) cal@amUiO-66. We used 
Hoechst 33342 (H33342) and propidium iodide (PI) for staining 
the nucleus of the cells and as a viability control, respectively. 
PI is unable to stain cells with intact membrane and has been 
widely used to assess the viability of cells.22 For fixed cells 
which have lost their cell membrane integrity, PI successfully 
stained them. However, for non-fixed cells, no PI signal was 
detected, indicating that the membranes of the cells containing 
the loaded UiO-66 were intact and consequently the cells were 
alive. This is particularly important in order to assess the 
crossing of cell the membrane by free drugs and DDS. Cells 
incubated with free calcein were not stained at 24 h of 
incubation and were only stained weakly in the form of bright 
vesicles at 48 h of incubation, suggesting that the dye is 
encapsulated in endosomes. Although calcein is believed not to 
penetrate the cell membrane, cellular uptake of impermeable 
dyes by endocytosis has been reported previously using Human 
Mesenchymal Stem Cells (MSCs) and the dye Lucifer yellow 
(LYCH).23 When the cells were incubated with cal@UiO-66, a 
strong signal was detected at 24 h, and the signal was 
intensified at 48 h because of the rapid delivery of the drug. 
This confirms that the cal@UiO-66 complex was effectively 
incorporated into the cells. The confocal images show punctate 
staining that suggests MOF entrapment within intracellular 
vesicles. Cells incubated with cal@amUiO-66 only showed a 
very weak signal after 24 h due to the self-quenching 
characteristic of calcein, and the signal was intensified at 48 h. 
Both at 24 and 48 h, the signal from cal@amUiO-66 was less 
intense than that obtained from crystalline cal@UiO-66. This 
difference is due to the slower release of calcein from the 
amorphous material, amUiO-66, as observed previously in the 
 
Figure 3. Confocal microscopy images of HeLa cells incubated for (a) 24 and (b) 
48 h. Cells were subsequently stained with Hoechst 33342 (5 g/ml) and PI (5 
g/ml). 
release assays. Additionally, for both forms of the material, the 
calcein signal detected is always stronger than the one obtained 
channel images are presented to have an integrated picture of 
the particle uptake by HeLa cells. 
In order to quantify the amount of internalised complex 
cal@UiO-66 and cal@amUiO-66, we performed flow 
cytometry measurements. Figure 4a and b show the two colour 
dot plot of HeLa cells incubated for 24 h for cal@UiO-66 and 
cal@amUiO-66, respectively. We used CellTrace calcein AM 
red/orange as viability control because it is retained by cells 
with intact cell membrane. The y-axis represents the 
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fluorescence intensity of CellTrace, whereas the x-axis 
represents the fluorescence of calcein due to the uptake of 
cal@UiO-66 or cal@amUiO-66. Figure 4c shows the average 
normalised calcein fluorescence of live cells that internalised 
either cal@UiO-66 or cal@ amUiO-66. On one hand, 
cytoplasmic calcein fluorescence from free calcein is 95% and 
92% lower than cal@UiO-66 and cal@amUiO-66, respectively. 
This is due to the less efficient internalisation of free calcein 
because its hydrophilic character. On the other hand, crystalline 
cal@UiO-66 shows stronger cytoplasmic calcein fluorescence 
than that of cal@amUiO-66 (41% lower for cal@amUiO-66 
compared to cal@UiO-66). As explained before this 
phenomenon is a consequence of the self-quenching 
characteristics of calcein and the faster release of cal@UiO-66 
compared to cal@amUiO-66.  
Figure 4. Flow cytometry two colour dot plot of HeLa cells incubated for 24 h 
with a) cal@UiO-66, and b) cal@amUiO-66; c) shows the cytoplasmic calcein 
fluorescence of cells incubated with cal@UiO-66, cal@amUiO-66 and free calcein. 
Error bars represent the standard error of three samples. Asterisks indicate: ** P 
≤ 0.01 and **** P ≤ 0.0001 in comparison with the cal@UiO-66 (Student’s test).  
Conclusions 
We have successfully loaded and released the hydrophilic 
model drug calcein into the Zr-based MOF UiO-66. We have 
shown how the structural collapse of UiO-66 around calcein 
through a ball-milling amorphization process allows the 
entrapment of the drug inside the porosity. By doing this, we 
were able to significantly increase drug release times from 2 to 
up to 30 days in a drug delivery system (DDS) with a particle 
size of 272 ± 157 nm. Such extremely long times have not been 
reported before for any MOF or other DDS with similar 
characteristics. This striking increase in the length of the 
delivery period is in principle a generally applicable technique 
not only to other MOFs but also other crystalline materials. 
Finally, we are reporting crystalline and amorphous DDS not 
only able to extend the release time but to penetrate into the 
cells while maintaining the kinetic characteristic of the 
delivery. This feature is extremely useful especially for 
impermeable drugs and drugs with poor solubility. Future work 
with active therapeutic agents to study the biological effect of 
the system is currently ongoing.  
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